Auvi-Q Epinephrine Auto Injector Back In Market With $360 Tag Price On Feb. 14

  • comments
  • print
  • email
Jan 23, 2017 09:02 PM EST

Kaleo pharmaceutical is re-launching its Auvi-Q epinephrine auto injector on Feb. 14. The EpiPen rival has been recalled in 2015 by the Food and Drug Administration (FDA)

According to a news report from The Washington Post, Kaleo, a Richmond, Va, based pharmaceutical company, will be bringing the Auvi-Q epinephrine back to the shelves on Feb. 14. Auvi-Q epinephrine is an auto injector that is used for immediate cure from severe allergic reactions.

Kaleo pharmaceutical's Auvi-Q epinephrine was recalled by the FDA in 2015. The FDA reportedly pulled out the epinephrine auto injector because of some manufacturing issues. The cause of the pull out was later revealed as the failure of the Auvi-Q to administer accurate dosages.

After the pull out of the Auvi-Q epinephrine in the market, its rival, the EpiPen remained as the only anti-allergy auto injector. Mylan NV, the pharmaceutical company behind the EpiPen has been subjected to tremendous criticism just recently because of the huge increase in the price of EpiPen.

The price of the auto inject sky rocketed to $600 this past year. According to Yahoo News, the EpiPen maker will be launching a generic version of the EpiPen to be sold for half the price.

According to reports, patients who do not have insurance, private or government, can purchase two-pack of Auvi-Q epinephrine for $360. The reports also suggest that the patients who do not have private or government insurance and belongs to a household with a combined income of less than $100,000 can get the Kaleo auto injector for free. This is also true for patients who have private insurance.

Patients who do not meet the $100,000 maximum teshhold will have to pay the $360 price. Spencer Williamson, CEO of Kaleo, claims that Auvi-Q gives commercially insured patient the least out-of-poket cost among all epinephrine auto injector in the market today, be it generic or branded. 

Join the Conversation
Real Time Analytics